Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05055648 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy

Study acronym: PROTECT
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Not applicable to Phase 3
    • Primary completion date: May 1, 2025 to Dec 1, 2027
    • Study sites: 13 to 15
    • Study completion date: May 1, 2030 to Dec 1, 2032
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Oct 1, 2024 to May 1, 2025
    • Start date changed from estimate of Oct 1, 2021 to May 1, 2022
    • Study completion date: Oct 1, 2029 to May 1, 2030
    • Site details revised at 13 of 13 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).
Trial Details
NCT Number NCT05055648
Lead Sponsor University of Aarhus
Collaborators: University of Leeds, KU Leuven, University College, London, Aarhus University Hospital, Technische Universität Dresden, Academisch Ziekenhuis Groningen, CNAO National Center of Oncological Hadrontherapy, Agenzia Nazionale per i Servizi Sanitari Regionali, Centre Antoine Lacassagne, Centre Leon Berard, Institut Curie, Maastro Clinic, The Netherlands, University College London Hospitals, The Christie NHS Foundation Trust, Paul Scherrer Institut, Center for Proton Therapy, HollandPTC, IBA worldwide, Varian- A Siemens Healthineer Company
Conditions
(from sponsor)		 Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy
Related terms Esophageal Neoplasms
Enrollment 396 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov